Leap Therapeutics cuts 75% workforce, winds down R&D, faces going-concern with $18.1M cash

Leap Therapeutics, Inc. (NASDAQ: LPTX) - quick read on what's going on inside the company and the income statement highlights. Amounts below are presented in the company's filing format (in thousands, except share and per share amounts).

Key facts & statistics
- Cash and cash equivalents: $18,130 (June 30, 2025).
- Total assets: $20,042; Total stockholders' equity: $5,717 (June 30, 2025).
- Accumulated deficit: $(499,449).
- Common shares outstanding: 41,439,529 (as disclosed).
- Weighted average common shares outstanding (basic & diluted): 41,444,979 (three months ended June 30, 2025).
- Net loss - three months ended June 30, 2025: $(16,643). Six months ended June 30, 2025: $(32,078).
- Net loss per share - three months: $(0.40); six months: $(0.78).
- Research & development expense - three months: $10,537; six months: $23,448.
- General & administrative expense - three months: $1,817; six months: $4,823.
- Restructuring charges recorded in Q2 2025: $4,527 (primarily severance and accelerated vesting).
- Total operating expenses - three months: $16,881; six months: $32,798.
- Net cash used in operating activities (six months): $(28,966).
- Cash at period start (Jan 1 / period-begin): $47,249; net decrease in cash: $(29,119) for six months ended June 30, 2025.
- Accounts payable: $7,339; Accrued expenses: $6,623 (June 30, 2025).
- Research & development incentive receivable: $798 (June 30, 2025).
- Stock-based compensation expense - three months: $1,489; six months: $2,693.
- Options outstanding: 5,031,973; Warrants issuable: 3,290,766 (various expirations/exercise prices).
- Board engaged Raymond James to explore strategic alternatives; workforce reduction impacted ~75% of employees; Company is winding down R&D programs (including sirexatamab and FL‑501) per board-approved actions.

What's happening inside the company - the short version
Leap is pivoting from an active clinical development posture to a capital-conservation and strategic‑alternatives process. Management and the Board have (1) substantially reduced headcount (≈75%), (2) recorded $4.5M of restructuring charges, (3) begun winding down its development activities (including completion of the DeFianCe trial and pausing further development of sirexatamab and FL‑501), and (4) engaged a financial advisor to evaluate M&A, asset sale, licensing or financing options. The company also amended its office lease to reduce space and cost.

Positive aspects (income statement & operational)
- R&D and G&A expenses declined year-over-year (Q2 2025 vs Q2 2024: R&D down $7.348M; G&A down $1.55M) - indicating immediate cost reduction.
- Cash preservation actions (headcount cuts, lease reduction) should lower future burn if sustained.
- Company participates in an Australian R&D incentive program (receivable $798) that provides partial reimbursement of eligible R&D costs.
- Stock-based compensation remains a non-cash component supporting expense management.

Negative aspects (income statement & balance sheet risks)
- Cash dropped to $18.13M from $47.25M (Dec 31, 2024) and operating cash use was ~$29M over six months - runway is limited.
- Management explicitly states "substantial doubt" about the company's ability to continue as a going concern for the next 12 months.
- Large accumulated deficit: $(499,449). Company continues to lose money (Q2 net loss $(16.6M)).
- Near-term charges (restructuring accruals $3.54M in accrued expenses) and potential transaction costs will pressure liquidity.
- Outstanding warrants and options (potential dilution of ~8.3M excluded anti-dilutive shares) and prior equity raises dilute existing holders if further financing is required.
- Wind-down of development programs reduces near-term R&D spend but also curtails the company's future revenue/asset value unless assets are sold/licensed on favorable terms.

Bottom line
Leap Therapeutics (NASDAQ: LPTX) is in a defensive transition: meaningful cost cuts and program wind‑down have lowered recurring spend, but cash has fallen sharply and the company reports substantial doubt about going concern. The near-term story hinges on the strategic‑alternative process (sale, licensing, partner, or fresh financing). For holders or prospective investors, the tradeoff is clear: potential value recovery via a transaction versus high risk of further dilution or liquidation if a deal or financing cannot be completed.

If you want, I can produce a one-page cheatsheet for investors (timeline of actions, cash/runway sensitivity, and key trigger events to watch).